Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | FABP3 | P05413 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420835 | 1.00 | GABRA1 (0.34) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL19469285 | 0.95 | GABRA1 (0.32) | GABRA1GABRB2FABP3FABP4FABP5 | |
| Formaldehyde SCHEMBL15282063 | 0.94 | FABP3 (0.33) | GABRA1GABRB2FABP3FABP4FABP5 | |
| SCHEMBL19514026 | 0.93 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL17513112 | 0.85 | — | — | |
| SCHEMBL29389074 | 0.85 | — | — | |
| SCHEMBL15696062 | 0.84 | FABP3 (0.33) | FABP3FABP4FABP5 | |
| SCHEMBL29786734 | 0.83 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL21114487 | 0.83 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL17946313 | 0.83 | GABRA1 (0.32) | GABRA1GABRB2FABP3FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725945-A1 | PREPARATION METHOD FOR FORMAMIDE COMPOUNDS | Shanghai Senhui Medicine Co., Ltd. (CN) | 2026-04-15 | — | — | EP | claimed |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | YALE UNIVERSITY (US) | 2025-02-25 | — | — | US | claimed |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-01-02 | — | — | US | claimed |
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2024-10-03 | — | — | US | claimed |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2024-08-27 | — | — | US | claimed |
| EP-4089087-B1 | METHOD FOR PREPARING PYRROLIDINYL UREA DERIVATIVE | ZHANGZHOU PIEN TZE HUANG PHARM (CN) | 2024-07-03 | — | — | EP | claimed |
| CN-117881670-A | Methods of making EGFR inhibitors | 缆图药品公司 | 2024-04-12 | — | — | CN | claimed |
| US-20240101516-A1 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | BASF SE (DE) | 2024-03-28 | — | — | US | claimed |
| EP-4277745-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | UVIC Industry Partnerships Inc. (CA) | 2023-11-22 | — | — | EP | claimed |
| WO-2014031791-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | claimed |
| US-8314232-B2 | Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide | GLAXOSMITHKLINE LLC (US) | 2012-11-20 | — | — | US | claimed |
| US-20120116109-A1 | PREPARATION OF A METAL COMPLEX | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2012-05-10 | — | — | US | claimed |
| EP-2432783-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-03-28 | — | — | EP | claimed |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | claimed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | EXELIXIS, INC. | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | GABRA1 3673/4885GABRB2 3852/4885FABP3 4406/4885 |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | GABRA1 4869/4885GABRB2 4867/4885FABP3 4873/4885 |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | GABRA1 601/4885GABRB2 566/4885FABP3 977/4885 |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | GABRA1 601/4885GABRB2 566/4885FABP3 977/4885 |
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | PDCD6IP, PDPK1, PDCD10 | GABRA1 3680/4885GABRB2 4150/4885FABP3 4046/4885 |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | GABRA1 2229/4885GABRB2 2937/4885FABP3 3504/4885 |
| US-20240101516-A1 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | AADAC, PAICS, PARN | GABRA1 458/4885GABRB2 650/4885FABP3 2702/4885 |
| US-20120014913-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, MAVS, RNASE1 | GABRA1 3622/4885GABRB2 3903/4885FABP3 4549/4885 |
| US-20120116109-A1 | PREPARATION OF A METAL COMPLEX | PDCD1LG2, CD274, PDCD2L | GABRA1 4184/4885GABRB2 3926/4885FABP3 4285/4885 |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | TET2, TIMCC, MDM4 | GABRA1 4826/4885GABRB2 4863/4885FABP3 4874/4885 |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | TIMCC, YAP1, TET2 | GABRA1 4869/4885GABRB2 4867/4885FABP3 4875/4885 |
| US-20100081805-A1 | Preparation of a Quinolinyloxydiphenylcyclopropanedicarboxamide | QDPR, CBR3, NQO2 | GABRA1 1823/4885GABRB2 915/4885FABP3 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.